Search

1205 Result(s)
Sort by

Pascal Haubert

Pascal Haubert

Three months into an internship with us, Pascal Haubert talks about responsibility, learning, and mutual support.
How BI Supports Grass Roots Innovation

How BI Supports Grass Roots Innovation

Hear from life-science entrepreneurs about how we are supporting early-stage science through our innovative Grass Roots program.
Living with GPP

Living with GPP

Video content showing a patient’s perspective of living with generalized pustular psoriasis (GPP), a rare skin condition
Rabies? Not in Mexico!

Rabies? Not in Mexico!

Mexico has been a rabies-free country for the last five years. How does Mexico achieve this? Learn how we're collaborating in this fight against rabies.
Disentangling fibrosis

Disentangling fibrosis

Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
World Patient Safety Day 2021

World Patient Safety Day 2021

As a sign of support for World Patient Safety Day, Boehringer Ingelheim lights up buildings in orange.
Really Digital, Mr Hach!

Really Digital, Mr Hach!

The Head of User Experience and SCRUM at Boehringer Ingelheim’s digital lab BI X offers a glimpse into his work and motivation.
FuturePack

FuturePack

Boehringer Ingelheim has built a new special machine that enables efficient and sustainable packaging of small batches.
Lothar Halmer

Lothar Halmer

Dr. Lothar Halmer is Chief Quality Officer and leads the Global Quality Organization in providing quality products for our patients every day.
Research Beyond Borders Partnering

Research Beyond Borders Partnering

Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
Be green Japan

Be green Japan

Boehringer Ingelheim's Yamagata site is gradually switching to a more sustainable energy supply.
FDA-approves-nintedanib-in-SSc-ILD

FDA-approves-nintedanib-in-SSc-ILD

FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD